Scarica l'app Stockscreener
17.54
0.75%
0.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$17.41
Aprire:
$17.87
Volume 24 ore:
7.20M
Relative Volume:
2.01
Capitalizzazione di mercato:
$13.61B
Reddito:
$220.00K
Utile/perdita netta:
$-1.08B
Rapporto P/E:
-12.14
EPS:
-1.4448
Flusso di cassa netto:
$-326.53M
1 W Prestazione:
+5.54%
1M Prestazione:
-15.79%
6M Prestazione:
-1.96%
1 anno Prestazione:
-33.08%
Intervallo 1D:
$17.36
$18.50
Intervallo di 1 settimana:
$15.89
$18.50
Portata 52W:
$13.83
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.54 | 13.51B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Experimental colorectal cancer drug sees 70.8% response rate in trial - Stock Titan
Behavioral Patterns of SMMT and Institutional Flows - Stock Traders Daily
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Bernstein reiterates Summit Therapeutics stock Underperform rating - Investing.com
Bernstein reiterates Summit Therapeutics stock Underperform rating By Investing.com - Investing.com Canada
Summit Therapeutics Inc. (SMMT) Stock Analysis: Biotech Player With 72% Potential Upside - DirectorsTalk Interviews
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - The Motley Fool
Bernstein initiates coverage of Summit Therapeutics (SMMT) with underperform recommendation - MSN
HC Wainwright & Co. downgrades Summit Therapeutics (SMMT) - MSN
SUPERSTRING CAPITAL MANAGEMENT LP's Summit Therapeutics Inc(SMMT) Holding History - GuruFocus
Summit Therapeutics Analyst Ratings and Price Targets | NASDAQ:SMMT - Benzinga
SMMT Initiates Coverage On Summit Therapeutics -- Rating Underpe - GuruFocus
Summit Therapeutics (SMMT) Faces Downgrade Amidst Competitive Pr - GuruFocus
Summit Therapeutics (SMMT) Downgraded to Neutral Amid Competitiv - GuruFocus
SMMT Downgraded by HC Wainwright & Co. -- Rating Changes to Neut - GuruFocus
Summit Therapeutics Shares Fall After HC Wainwright Downgrade - Moomoo
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For FridayCentene (NY - Benzinga
Summit downgraded at H.C. Wainwright after Merck data for sac-TMT - Seeking Alpha
Summit Therapeutics Price Target Announced at $7.70/Share by Bernstein - Moomoo
Why is Summit Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Here's Why You Should Add SMMT Stock to Your Portfolio Now - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
S&P 500 Futures Climb In Premarket Trading; WR Berkley, Summit Therapeutics Lag - Moomoo
H.C. Wainwright downgrades Summit Therapeutics stock rating to neutral By Investing.com - Investing.com Canada
Bernstein Initiates Summit Therapeutics at Underperform - Moomoo
HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy - Moomoo
H.C. Wainwright Downgrades Summit Therapeutics(SMMT.US) to Hold Rating - Moomoo
Summit Therapeutics (SMMT) Faces Scrutiny with Underperform Rati - GuruFocus
Bernstein downgrades Summit Therapeutics stock rating on trial concerns By Investing.com - Investing.com Canada
Summit Therapeutics Inc.Common Stock (NQ: SMMT - The Chronicle-Journal
Cancer Stocks That Are Advancing the Future of Oncology Care - Yahoo! Finance Canada
Summit Therapeutics Inc. (SMMT) Stock Analysis: Healthcare Innovator with Potential 74% Upside - DirectorsTalk Interviews
(SMMT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Look At Summit Therapeutics (SMMT) Valuation After HARMONi-3 Trial Risk Highlighted By Analyst Commentary - Yahoo Finance
H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) - Insider Monkey
Summit Therapeutics falls after update on Akeso-partnered lung cancer trial - MSN
8 Most Promising Biotech Stocks to Buy Now - Insider Monkey
Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply - simplywall.st
Summit Therapeutics Inc (SMMT) News, Articles, Events & Latest Updates - Stocktwits
Q2 EPS Estimate for Summit Therapeutics Boosted by Analyst - MarketBeat
Q2 Earnings Forecast for SMMT Issued By HC Wainwright - MarketBeat
How (SMMT) Movements Inform Risk Allocation Models - Stock Traders Daily
JPM: AKESO (09926.HK) Lung Cancer Trial Final Analysis Likely to Meet Target; Rating Overweight - AASTOCKS.com
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III - BioWorld News
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback - Yahoo Finance
Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary (NASDAQ:SMMT) - Seeking Alpha
Investigation into Summit Therapeutics by Johnson Fistel - Intellectia AI
Summit Therapeutics Inc. Shareholders Are Encouraged to - GlobeNewswire
SMMT Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk - Investing.com Canada
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
0.37%
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):